- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05896566
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (PREcoopERA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objectives are:
- to determine if 4 weeks of giredestrant plus triptorelin provides greater anti-proliferative activity than anastrozole plus triptorelin among premenopausal patients with ER-positive/HER2-negative operable invasive breast cancer.
- to determine if 4 weeks of giredestrant without triptorelin provides anti-proliferative activity that is similar (non-inferior) to giredestrant plus triptorelin among premenopausal patients with ER-positive/HER2-negative operable invasive breast cancer.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Heidi Roschitzki, PhD
- Phone Number: +41 31 511 94 00
- Email: heidi.roschitzki@etop.ibcsg.org
Study Locations
-
-
-
Villejuif, France
- Not yet recruiting
- Gustave Roussy Cancer Center
-
Contact:
- Barbara Pistilli
-
-
-
-
-
Berlin, Germany
- Recruiting
- Helios Klinikum Berlin Buch
-
Contact:
- Michael Untch
- Email: michael.untch@helios-gesundheit.de
-
Berlin, Germany
- Not yet recruiting
- Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR
-
Contact:
- Oskay Öczelik
- Email: studienoskay@medionko.de
-
Essen, Germany
- Not yet recruiting
- KEM / Kliniken Essen Mitte
-
Contact:
- Mattea Reinisch
- Email: m.reinisch@kem-med.com
-
Frankfurt, Germany
- Not yet recruiting
- Klinikum der J. W. Goethe Universität
-
Contact:
- Christine Solbach
- Email: kfg-brustzentrum@kgu.de
-
Kiel, Germany
- Not yet recruiting
- Universitätsklinikum Schleswig-Holstein
-
Contact:
- Marion van Mackelenbergh
- Email: MarionTina.vanMackelenbergh@uksh.de
-
Leipzig, Germany
- Recruiting
- St. Elisabeth Krankenhaus
-
Contact:
- Dagmar Langanke
- Email: dagmar.langanke@ek-leipzig.de
-
Mannheim, Germany
- Not yet recruiting
- Universitätsklinikum Mannheim GmbH
-
Contact:
- Frederik Marme
- Email: Frederik.Marme@umm.de
-
Rostock, Germany
- Not yet recruiting
- Klinikum Südstadt
-
Contact:
- Toralf Reimer
- Email: toralf.reimer@kliniksued-rostock.de
-
Ulm, Germany
- Not yet recruiting
- Universitatsklinikum Ulm
-
Contact:
- Brigitte Rack
- Email: Rack_Studien.UFK@uniklinik-ulm.de
-
Wuppertal, Germany
- Recruiting
- Helios Klinikum Wuppertal GmbH
-
Contact:
- Vesna Bjelic-Radisic
- Email: Vesna.Bjelic-Radisic@helios-gesundheit.de
-
-
-
-
-
Budapest, Hungary
- Not yet recruiting
- National Institute of Oncology
-
Contact:
- Balazs Madaras
-
-
-
-
-
Cork, Ireland
- Not yet recruiting
- Cork University Hospital
-
Contact:
- Roisin Connolly
-
Dublin, Ireland
- Not yet recruiting
- St. James Hospital
-
Contact:
- Ciara O'Hanlon Brown
-
Galway, Ireland
- Not yet recruiting
- University Hospital Galway
-
Contact:
- Maccoon Keane
-
-
-
-
-
Ancona, Italy
- Not yet recruiting
- Clinica Oncologica AOU Riuniti Ancona
-
Contact:
- Rossana Berardi
- Email: Rossana.Berardi@ospedaliriuniti.marche.it
-
Bergamo, Italy
- Not yet recruiting
- Humanitas Gavazzeni
-
Contact:
- Fabio Conforti
- Email: fabio.conforti@gavazzeni.it
-
Brindisi, Italy
- Not yet recruiting
- ASL BR Azienda Sanitaria Locale
-
Contact:
- Saverio Cinieri
- Email: saverio.cinieri@asl.brindisi.it
-
Genova, Italy
- Not yet recruiting
- IRCCS Ospedale Policlinico San Martino
-
Contact:
- Matteo Lambertini
- Email: matteo.lambertini@unige.it
-
Meldola, Italy
- Recruiting
- Istituto oncologico romagnolo per lo studio dei tumori "Dino Amadori"
-
Contact:
- Ugo De Giorgi
- Email: ugo.degiorgi@irst.emr.it
-
Milano, Italy
- Not yet recruiting
- Istituto Europeo di Oncologia
-
Contact:
- Elisabetta Munzone
- Email: elisabetta.munzone@ieo.it
-
Novara, Italy
- Not yet recruiting
- AOU Maggiore della Carità
-
Contact:
- Alessandra Gennari
- Email: alessandra.gennari@med.uniupo.it
-
Pavia, Italy
- Not yet recruiting
- Istituti Clinici Scientifici Maugeri SpA-SB
-
Contact:
- Laura Deborah Locati
- Email: lauradeborah.locati@icsmaugeri.it
-
Prato, Italy
- Not yet recruiting
- Azienda USL Toscana Centro
-
Contact:
- Laura Biganzoli
- Email: laura.biganzoli@uslcentro.toscana.it
-
Rimini, Italy
- Not yet recruiting
- Rimini Oncology department
-
Contact:
- Lorenzo Gianni
- Email: lorenzo.gianni@auslromagna.it
-
Roma, Italy
- Not yet recruiting
- Fondazione Policlinico Gemelli Medical Oncology Unit
-
Contact:
- Emilio Bria
- Email: emilio.bria@policlinicogemelli.it
-
Roma, Italy
- Not yet recruiting
- Policlinico universitario Agostino Gemelli IRCCS Rome
-
Contact:
- Alessandra Fabi
- Email: alessandra.fabi@policlinicogemelli.it
-
-
-
-
-
Badajoz, Spain
- Not yet recruiting
- Complejo Hospitalario Universitario Badajoz
-
Contact:
- Alba González-Haba Martínez
-
Badalona, Spain
- Not yet recruiting
- Institut Catala D'oncologia ICO-Badalona
-
Contact:
- Milana Bergamino
- Email: milana.bergamino@iconcologia.net
-
Barcelona, Spain
- Not yet recruiting
- Institut Catala d'Oncologia - Hospitalet
-
Contact:
- Verónica Luisa Obadia Gil
-
Lleida, Spain
- Not yet recruiting
- H.U. Arnau de Vilanova de Lleida
-
Contact:
- Serafín Morales
- Email: smorales.lleida.ics@gencat.cat
-
Madrid, Spain
- Not yet recruiting
- Fundacion Jimenez Diaz
-
Contact:
- Yann Izarzugaza
- Email: yizarzugaza@fjd.es
-
Madrid, Spain
- Not yet recruiting
- CIOCC (Centro Integral Oncológico Clara Campal)
-
Contact:
- Beatriz Rojas Garcia
- Email: Beatrizrojas1981@gmail.com
-
Palma De Mallorca, Spain
- Not yet recruiting
- Hospital Universitari Son Espases
-
Contact:
- Antonia Perello
- Email: antonia.perellom@ssib.es
-
Valencia, Spain
- Not yet recruiting
- H. la Fé
-
Contact:
- Helena de la Cueva
- Email: delacueva_hel@gva.es
-
-
-
-
-
Gothenburg, Sweden
- Not yet recruiting
- Sahlgrenska Comprehensive Cancer Center
-
Contact:
- Per Karlsson
- Email: per.karlsson@oncology.gu.se
-
-
-
-
-
Baden, Switzerland
- Not yet recruiting
- Kantonsspital Baden AG
-
Contact:
- Cornelia Leo
-
Basel, Switzerland
- Recruiting
- Praxis Dr. Thorn, Praxis fur ambulante Tumortherapie (Praxis Thorn (Bethesda))
-
Contact:
- David Thorn
-
Bellinzona, Switzerland
- Not yet recruiting
- Onc Inst of Southern Switzerland (IOSI)
-
Contact:
- Lorenzo Rossi
-
Fribourg, Switzerland
- Not yet recruiting
- Centre du Sein (Hopital Fribourgeois-Freiburger Spital)
-
Contact:
- Laurent Rosset
-
La Chaux-de-Fonds, Switzerland
- Not yet recruiting
- La Chaux-de-fonds, RH Neuchatelois (Hopital Les Cadolles)
-
Contact:
- Agnes Auteri
-
Luzern, Switzerland
- Recruiting
- St. Anna Hirslanden
-
Contact:
- Peter Dubsky
-
Thurgau, Switzerland
- Recruiting
- Brustzentrum Thurgau ( Spital AG)
-
Contact:
- Mathias Fehr
-
Zürich, Switzerland
- Recruiting
- Universitiy Hospital Zurich
-
Contact:
- Isabel Witzel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Premenopausal women age ≥18 years, premenopausal status defined as:
Estradiol (E2) in the premenopausal range (according to institution parameters) or Patient has been menstruating regularly during the 6 months prior to screening and has not used any form of hormonal contraception or any other hormonal treatments during this time.
- Histologically confirmed, operable invasive breast carcinoma.
- Eligible for upfront breast conservative surgery or upfront mastectomy: stage I, stage II or operable stage III (excludes T4) (AJCC Cancer Staging Manual 8th edition 2017).46 Tumor size must be ≥1.0 cm Multicentric and multifocal tumors and bilateral breast cancers are allowed but investigators must ensure the same tumor foci is biopsied pre-treatment and post-treatment (e.g., via clipping of the biopsied tumor foci).
- Documented estrogen receptor (ER)-positive tumor in accordance to ASCO/CAP guidelines (Allison et al. 2020),47 assessed locally and defined as ≥1% of tumor cells stained positive.
- Documented human epidermal growth factor receptor-2 (HER2)-negative tumor in accordance to 2018 ASCO/CAP guidelines (Wolff et al. 2018)48, as determined per local assessment.
- Ki 67 ≥10% in diagnostic biopsy as determined per local assessment.
- Eastern Cooperative Oncology Group Performance Status 0-1.
- Resting heart rate ≥40 bpm.
- Normal hematologic status
- Normal renal function
- Normal liver function
- INR <1.5× ULN and PTT <1.5x ULN Except for patients receiving anticoagulation therapy. For patients receiving warfarin, a stable INR between 2 and 3 is required. For patients receiving heparin, PTT between 1.5 and 2.5 x ULN (or value before patient started heparin treatment) is required.
If anticoagulation therapy is required for a prosthetic heart valve, stable INR between 2.5 and 3.5 is permitted.
- Negative serum or urine beta HCG pregnancy test within 5 weeks prior to randomization.
Pregnancy test will be repeated on day 1, before the first dose of WOO treatment.
Women of childbearing potential must use highly effective contraceptive methods during the treatment period and for 10 days after the final dose.
- Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to randomization.
- The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
- The patient agrees to the submission of tumor (diagnostic pre-treatment core biopsy and post-treatment re-biopsy) and blood samples for central pathology review (CPR) and for translational studies as part of this protocol.
Exclusion Criteria:
- Stage IV (metastatic) breast cancer.
- Inflammatory breast cancer (cT4d).
- Previous systemic or local treatment for the primary breast cancer currently under investigation.
- Received any GnRH/LHRH analog within 12 months prior to randomization
- Major surgery within 4 weeks prior to randomization.
- Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including hepatitis.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- History of documented hemorrhagic diathesis, coagulopathy, or thromboembolism.
- Active cardiac disease or history of cardiac dysfunction, including any of the following:
History or presence of symptomatic bradycardia or resting heart rate <50 bpm at screening. Patients on stable dose of a beta-blocker or calcium channel antagonist for pre-existing baseline conditions (e.g., hypertension) may be permitted if resting heart rate is ≥50 bpm.
History of angina pectoris, symptomatic pericarditis, myocardial infarction, or any cardiac arrhythmias (e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality) within 12 months prior to study entry History of documented congestive heart failure (New York Heart Association Class II-IV) or cardiomyopathy Left ventricular ejection fraction <50% as determined by multiple-gated acquisition scan or echocardiogram QT interval corrected through use of Fridericia's formula (QTcF) >470 ms based on mean value of triplicate ECGs, history of long or short QT syndrome, Brugada syndrome or known history of corrected QT interval prolongation, or torsades de pointes History or presence of an abnormal ECG that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, sick sinus syndrome, or evidence of prior myocardial infarction
- History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of long QT syndrome.
- Current treatment with medications that are well known to prolong the QT interval.
- Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment.
- Known issues with swallowing oral medication.
- Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or major upper gastrointestinal surgery including gastric resection.
- Serious infection requiring oral or IV antibiotics, or other clinically significant infection within 14 days prior to screening.
- Any active tumor of non-breast-cancer histology.
- Women who are pregnant or in the period of lactating.
- Any concurrent disease or serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study.
- Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
- Contraindications or known hypersensitivity to the trial medication or excipients.
- Treatment with any investigational agents within 30 days prior to expected start of trial treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: Giredestrant
Giredestrant
|
Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
|
Experimental: Arm B: Giredestrant plus triptorelin
Giredestrant plus triptorelin
|
Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
Triptorelin: 3.75 mg IM on day 1.
Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
|
Active Comparator: Arm C: Anastrozole plus triptorelin
Anastrozole plus triptorelin
|
Triptorelin: 3.75 mg IM on day 1.
Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Ki 67
Time Frame: From date of randomisation until 29 ±3 days post-randomisation
|
The primary endpoint is the change in Ki 67 (Ki 67-labeling index, the percentage immunostaining cells measured by IHC in central laboratory) between the pre-treatment tumor biopsy and a post-treatment tumor re-biopsy (analyzed on the natural logarithm scale).
|
From date of randomisation until 29 ±3 days post-randomisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete cell cycle arrest (CCCA)
Time Frame: From date of randomisation until 29 ±3 days post-randomisation
|
Complete cell cycle arrest (CCCA), defined as Ki 67 ≤2.7% on the post -treatment tumor re-biopsy on day 29 (±3 days), by visual image analysis.
|
From date of randomisation until 29 ±3 days post-randomisation
|
Adverse events according to CTCAE v5.0
Time Frame: From the date of enrolment until last patient last visit (approximately 28 months after randomisation of the first patient)]
|
Record all AEs (including SAEs and AESIs) and assign the appropriate grade according to the CTCAE v5.0.
|
From the date of enrolment until last patient last visit (approximately 28 months after randomisation of the first patient)]
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Elisabetta Munzone, MD, European Institute of Oncology, Milano
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Luteolytic Agents
- Triptorelin Pamoate
- Anastrozole
Other Study ID Numbers
- IBCSG 67-22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Giredestrant
-
Hoffmann-La RocheRecruitingEndometrial CancerUnited States, Canada, Italy, Poland
-
Fondazione OncotechNot yet recruiting
-
Genentech, Inc.CompletedBreast CancerUnited States, Spain, Belgium, Australia, United Kingdom
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, Peru and more
-
Genentech, Inc.CompletedHealthy VolunteersUnited States
-
MedSIRNot yet recruiting
-
Austin V StoneNot yet recruitingMeniscus Lesion | Meniscus Tear | Meniscus Disorder | Meniscus; DerangementUnited States
-
Hoffmann-La RocheRecruitingEarly Breast CancerUnited States, Spain, France, Korea, Republic of, China, Italy, Taiwan, Sweden, Czechia, Hungary, Japan, Greece, Hong Kong, Ukraine, Australia, Brazil, Canada, Mexico, Belgium, Kenya, Argentina, Chile, Serbia, South Africa, Colombia, Ireland and more
-
Genentech, Inc.CompletedHealthy VolunteersUnited Kingdom
-
Genentech, Inc.Active, not recruitingBreast CancerUnited States, Spain, Korea, Republic of, Australia, United Kingdom